Skip to search formSkip to main contentSkip to account menu

marimastat

Known as: (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid, (2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid, Marimistat 
An orally-active synthetic hydroxamate with potential antineoplastic activity. Marimastat covalently binds to the zinc(II) ion in the active site of… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

BB-2516TA-2516

Broader (2)

Enzyme InhibitorsHydroxamic Acids
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
A novel androgen signalling pathway uses dihydrotestosterone, but not testosterone, to activate the EGF receptor signalling cascade in prostate stromal cells
Human prostate growth and function are tightly controlled by androgens that are generally thought to exert their effects by… 
Review
2013
Review
2013
Molecular targets in the discovery and development of novel antimetastatic agents: Current progress and future prospects
Tumour invasion and metastasis have been recognized as major causal factors in the morbidity and mortality among cancer patients… 
Review
2003
Review
2003
Angiogenesis inhibitors under study for the treatment of lung cancer.
Review
2003
Review
2003
Marimastat: BB 2516, TA 2516.
Marimastat [BB 2516, TA 2516] is a second-generation anticancer drug originally developed with British Biotech in Europe and… 
2002
2002
Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
We investigated the effects of marimastat, an inhibitor of TNF-alpha converting enzyme and matrix metalloproteinases, and anti… 
2002
2002
Matrix metalloproteinase inhibitor therapy to prevent complications as well as therapy for Ehler-Danlos syndrome.
2002
2002
Inhibition of metalloproteinases enhances the internalization of anti‐CD30 antibody Ki‐3 and the cytotoxic activity of Ki‐3 immunotoxin
CD30 is selectively expressed on the tumor cells of a variety of malignant disorders of the immune system and can therefore be… 
Review
2001
Review
2001
Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer.
2000
2000
Effect of marimastat on serum tumour markers in patients with colorectal cancer.
BACKGROUND Matrix metalloproteinases (MMPs) are a family of enzymes that break down extra cellular matrix proteins during tissue… 
2000
2000
Prognostic Role of K-ras in Patients with Progressive Colon Cancer Who Received Treatment with Marimastat (BB2516)
Abstract We determined the prognostic role of K-ras mutation in tumor tissue of patients with refractory colon cancer who… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)